Search

Your search keyword '"Staudinger, Heribert"' showing total 259 results
Start Over Author "Staudinger, Heribert"
259 results on '"Staudinger, Heribert"'

2. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study

Author

Bacharier, Leonard B., Maspero, Jorge F., Katelaris, Constance H., Fiocchi, Alessandro G., Gagnon, Remi, De Mir, Ines, Guilbert, Theresa W., Jackson, Daniel J., Staudinger, Heribert W., Laws, Elizabeth, Mannent, Leda P., Akinlade, Bolanle, Maloney, Jennifer, Tawo, Kelsey, Khokhar, Faisal A., Li, Ning, Hardin, Megan, Abdulai, Raolat M., Lederer, David J., Robinson, Lacey B., Bacharier, Leonard B, Maspero, Jorge F, Katelaris, Constance H, Fiocchi, Alessandro G, de Mir, Ines, Guilbert, Theresa W, Jackson, Daniel J, Staudinger, Heribert W, Mannent, Leda P, Khokhar, Faisal A, Abdulai, Raolat M, Lederer, David J, and Robinson, Lacey B

Published
2024
Full Text
View/download PDF

3. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

Author

Maurer, Marcus, Casale, Thomas B., Saini, Sarbjit S., Ben-Shoshan, Moshe, Giménez-Arnau, Ana M., Bernstein, Jonathan A., Yagami, Akiko, Stjepanovic, Aleksandra, Radin, Allen, Staudinger, Heribert W., Patel, Naimish, Amin, Nikhil, Akinlade, Bolanle, Fan, Chunpeng, Bauer, Deborah, Yancopoulos, George D., Patel, Kiran, Mannent, Leda P., and Laws, Elizabeth

Published
2024
Full Text
View/download PDF

6. AERIFY-1/-2: 2 phase 3 randomised controlled trials of itepekimab in former smokers with moderate-to-severe COPD

Author

Rabe, Klaus F., primary, Martinez, Fernando J., additional, Bhatt, Surya P., additional, Kawayama, Tomotaka, additional, Cosio, Borja G., additional, Mroz, Robert M., additional, Boomsma, Maarten M., additional, Goulaouic, Helene, additional, Nivens, Michael C., additional, Djandji, Michel, additional, Soler, Xavier, additional, Liu, Ying, additional, Kosloski, Matthew P., additional, Xu, Christine R., additional, Amin, Nikhil, additional, Staudinger, Heribert, additional, Lederer, David J., additional, and Abdulai, Raolat M., additional

Published
2024
Full Text
View/download PDF

8. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial

Author

Rabe, Klaus F, Celli, Bartolome R, Wechsler, Michael E, Abdulai, Raolat M, Luo, Xiaodong, Boomsma, Maarten M, Staudinger, Heribert, Horowitz, Julie E, Baras, Aris, Ferreira, Manuel A, Ruddy, Marcella K, Nivens, Michael C, Amin, Nikhil, Weinreich, David M, Yancopoulos, George D, and Goulaouic, Helene

Published
2021
Full Text
View/download PDF

9. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study

Author

Bacharier, Leonard B, primary, Maspero, Jorge F, additional, Katelaris, Constance H, additional, Fiocchi, Alessandro G, additional, Gagnon, Remi, additional, de Mir, Ines, additional, Guilbert, Theresa W, additional, Jackson, Daniel J, additional, Staudinger, Heribert W, additional, Laws, Elizabeth, additional, Mannent, Leda P, additional, Akinlade, Bolanle, additional, Maloney, Jennifer, additional, Tawo, Kelsey, additional, Khokhar, Faisal A, additional, Li, Ning, additional, Hardin, Megan, additional, Abdulai, Raolat M, additional, Lederer, David J, additional, Robinson, Lacey B, additional, Bacharier, Leonard B., additional, Maspero, Jorge F., additional, Katelaris, Constance H., additional, Fiocchi, Alessandro G., additional, De Mir, Ines, additional, Guilbert, Theresa W., additional, Jackson, Daniel J., additional, Staudinger, Heribert W., additional, Mannent, Leda P., additional, Khokhar, Faisal A., additional, Abdulai, Raolat M., additional, Lederer, David J., additional, and Robinson, Lacey B., additional

Published
2023
Full Text
View/download PDF

12. A first‐in‐human, single and multiple dose study of lunsekimig, a novel anti‐TSLP/anti‐IL‐13 NANOBODY® compound, in healthy volunteers.

Author

Deiteren, Annemie, Bontinck, Lieselot, Conickx, Griet, Vigan, Marie, Dervaux, Nele, Gassiot, Matthieu, Bas, Selcuk, Suratt, Benjamin, Staudinger, Heribert, and Krupka, Emmanuel

Subjects
THYMIC stromal lymphopoietin, IMMUNE response, VOLUNTEERS, VOLUNTEER service
Abstract

Lunsekimig is a novel, bispecific NANOBODY® molecule that inhibits both thymic stromal lymphopoietin (TSLP) and interleukin (IL)‐13, two key mediators of asthma pathophysiology. In this first‐in‐human study, we evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of lunsekimig in healthy adult participants. Participants received single ascending doses (SAD) of lunsekimig (10–400 mg intravenous [IV] or 400 mg subcutaneous [SC]) (SAD part) or multiple ascending doses (MAD part) of lunsekimig (100 or 200 mg, every 2 weeks [Q2W] for three SC doses), or placebo. Overall, 48 participants were randomized 3:1 in the SAD part and 4:1 in the MAD part for lunsekimig or placebo. The primary endpoint was safety and tolerability. The secondary endpoints included PK, antidrug antibodies (ADAs) and total target measurement. Lunsekimig was well tolerated and common treatment‐emergent adverse events were COVID‐19, nasopharyngitis, injection site reactions, and headache. Lunsekimig showed dose‐proportional increases in exposure and linear elimination. Mean t1/2z of lunsekimig was around 10 days across all IV and SC doses of the SAD and MAD parts of the study. Increases in the serum concentration of total TSLP and IL‐13 for lunsekimig versus placebo indicated target engagement. ADA of low titers were detected in four (11.1%) participants who received lunsekimig in the SAD, and seven (43.8%) in the MAD. In conclusion, lunsekimig was well tolerated in healthy participants with a linear PK profile up to single 400 mg IV and SC dose and multiple doses of 100 and 200 mg SC Q2W, with low immunogenicity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Blood eosinophils and FeNO are prognostic and predictive biomarkers in childhood asthma

Author

Bacharier, Leonard B., primary, Pavord, Ian D., additional, Maspero, Jorge F., additional, Jackson, Daniel J., additional, Fiocchi, Alessandro G., additional, Mao, Xuezhou, additional, Jacob-Nara, Juby A., additional, Deniz, Yamo, additional, Laws, Elizabeth, additional, Mannent, Leda P., additional, Amin, Nikhil, additional, Akinlade, Bolanle, additional, Staudinger, Heribert W., additional, Lederer, David J., additional, and Hardin, Megan, additional

Published
2024
Full Text
View/download PDF

15. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial

Author

Tashkin, Donald P, Doherty, Dennis E, Kerwin, Edward, Matiz-Bueno, Carlos E, Knorr, Barbara, Shekar, Tulin, Banerjee, Sibabrata, and Staudinger, Heribert

Subjects
Clinical Research, Lung, Patient Safety, Clinical Trials and Supportive Activities, Chronic Obstructive Pulmonary Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Respiratory, Administration, Inhalation, Adult, Area Under Curve, Bronchodilator Agents, Double-Blind Method, Drug Administration Schedule, Drug Combinations, Ethanolamines, Female, Formoterol Fumarate, Humans, Male, Metered Dose Inhalers, Middle Aged, Mometasone Furoate, Pregnadienediols, Pulmonary Disease, Chronic Obstructive, Respiratory Function Tests, Severity of Illness Index, Smoking, Spirometry, Surveys and Questionnaires, Treatment Outcome, chronic obstructive pulmonary disease, FEV1, spirometry, exacerbation, inhaled corticosteroid, bronchodilator, Cardiorespiratory Medicine and Haematology, Respiratory System
Abstract

BackgroundA clinical trial of mometasone furoate/formoterol fumarate (MF/F) administered via a metered-dose inhaler in subjects with moderate to very severe chronic obstructive pulmonary disease (COPD) investigated the efficacy and safety of a fixed-dose combination of MF/F.MethodsThis multicenter, double-blind, placebo-controlled trial had a 26-week treatment period and a 26-week safety extension. Subjects (n = 1055; ≥40 years) were current or ex- smokers randomized to twice-daily treatment with inhaled MF/F 400/10 μg, MF/F 200/10 μg, MF 400 μg, F 10 μg, or placebo. The coprimary endpoints of the trial were mean changes from baseline in forced expiratory volume in 1 second (FEV(1)) over 0-12 hours (AUC(0-12) FEV(1)) with MF/F versus MF, and in morning predose FEV(1) with MF/F versus F. Key secondary endpoints were quality of life (Saint George's Respiratory Questionnaire [SGRQ]), symptom-free nights, and partly stable COPD at 26 weeks, as well as time to first COPD exacerbation.ResultsSignificant improvements in FEV(1) AUC(0-12) occurred at endpoint with MF/F 400/10 and MF/F 200/10 versus MF 400 (P ≤ 0.007). Significant bronchodilation occurred in 5 minutes with MF/F, and serial spirometry demonstrated sustained FEV(1) improvements with MF/F over the treatment period. Significant improvements in morning predose FEV(1) occurred with both MF/F doses, and these effects were further investigated by excluding results for subjects whose morning FEV(1) data were collected >2 days after the last dose of study treatment. Improvements in SGRQ total scores surpassed the minimum clinically important difference of at least 4 units with MF/F 400/10. MF/F 400/10 significantly reduced the time-to-first COPD exacerbation. Similar proportions of subjects in all five treatment groups reported treatment-emergent adverse events. Rates of pneumonia were low (≤1.0%) across treatment groups.ConclusionMF/F 400/10 μg twice daily was shown to be an effective therapy for patients with moderate to very severe COPD, and both MF/F 400/10 μg twice daily and MF/F 200/10 μg twice daily were well tolerated.

Published
2012

16. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials

Author

Tashkin, Donald P, Doherty, Dennis E, Kerwin, Edward, Matiz-Bueno, Carlos E, Knorr, Barbara, Shekar, Tulin, Gates, Davis, and Staudinger, Heribert

Subjects
Lung, Patient Safety, Clinical Trials and Supportive Activities, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Respiratory, Administration, Inhalation, Adult, Area Under Curve, Bronchodilator Agents, Double-Blind Method, Drug Combinations, Ethanolamines, Female, Formoterol Fumarate, Humans, Male, Metered Dose Inhalers, Middle Aged, Mometasone Furoate, Pregnadienediols, Pulmonary Disease, Chronic Obstructive, Respiratory Function Tests, Severity of Illness Index, Smoking, Surveys and Questionnaires, Treatment Outcome, COPD, spirometry, exacerbation, inhaled corticosteroid, bronchodilator, Cardiorespiratory Medicine and Haematology, Respiratory System
Abstract

BackgroundThe clinical efficacy and safety of a mometasone furoate/formoterol fumarate (MF/F) fixed-dose combination formulation administered via a metered-dose inhaler was investigated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).MethodsTwo 52-week, multicenter, double-blind, placebo-controlled trials with identical study designs were conducted in current or ex-smokers (aged ≥40 years), and pooled study results are presented herein. Subjects (n = 2251) were randomized to 26 weeks of twice-daily treatment with MF/F 400/10 μg, MF/F 200/10 μg, MF 400 μg, F 10 μg, or placebo. After the 26-week treatment period, placebo subjects completed the trial and 75% of subjects on active treatment entered a 26-week safety extension. Coprimary efficacy variables were mean changes in forced expiratory volume in one second (FEV(1)), area under the curve from 0 to 12 hours postdose (AUC(0-12 h)), and morning predose/trough FEV(1) from baseline to the week 13 endpoint. Key secondary efficacy variables were St George's Respiratory Questionnaire scores, symptom-free nights, time-to-first exacerbation, and partly stable COPD at the week 26 endpoint.ResultsIn the 26-week treatment period, significantly greater increases in FEV(1) AUC(0-12 h) occurred with MF/F 400/10 versus MF 400 and placebo at the week 13 and week 26 endpoints (P ≤ 0.032). These increases were over three-fold greater with MF/F 400/10 than with MF 400. Also, significantly greater increases in morning predose/trough FEV(1) occurred with MF/F 400/10 versus F 10 and placebo at the week 13 endpoint (P < 0.05). The increase was four-fold greater with MF/F 400/10 than with F 10. All active treatment groups achieved minimum clinically important differences from baseline (>4 units) in St George's Respiratory Questionnaire scores at week 26. Symptom-free nights increased by ≥14% in the MF/F 400/10, MF 400, and F 10 groups (P ≤ 0.033 versus placebo). The incidence of exacerbations was lower in the MF/F groups (≤33.3%) than it was in the MF, formoterol, and placebo groups (≥33.8%) over the 26-week treatment period. The incidence of adverse events was similar in the active-treated and placebo-treated subjects across 26 weeks of treatment. Over the 1-year study period, there were no notable differences in the incidence or types of adverse events between the MF/F 400/10 and MF/F 200/10 groups compared with the MF or formoterol groups. Differences in rates of individual treatment-emergent adverse events were

Published
2012

17. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

Author

Bhatt, Surya P., primary, Rabe, Klaus F., additional, Hanania, Nicola A., additional, Vogelmeier, Claus F., additional, Cole, Jeremy, additional, Bafadhel, Mona, additional, Christenson, Stephanie A., additional, Papi, Alberto, additional, Singh, Dave, additional, Laws, Elizabeth, additional, Mannent, Leda P., additional, Patel, Naimish, additional, Staudinger, Heribert W., additional, Yancopoulos, George D., additional, Mortensen, Eric R., additional, Akinlade, Bolanle, additional, Maloney, Jennifer, additional, Lu, Xin, additional, Bauer, Deborah, additional, Bansal, Ashish, additional, Robinson, Lacey B., additional, and Abdulai, Raolat M., additional

Published
2023
Full Text
View/download PDF

18. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

Author

Busse, William W., Maspero, Jorge F., Rabe, Klaus F., Papi, Alberto, Wenzel, Sally E., Ford, Linda B., Pavord, Ian D., Zhang, Bingzhi, Staudinger, Heribert, Pirozzi, Gianluca, Amin, Nikhil, Akinlade, Bolanle, Eckert, Laurent, Chao, Jingdong, Graham, Neil M. H., and Teper, Ariel

Published
2018
Full Text
View/download PDF

19. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA)

Author

Khaleva, Ekaterina, Rattu, Anna, Brightling, Chris, Bush, Andrew, Bossios, Apostolos, Bourdin, Arnaud, Chung, Kian Fan, Chaudhuri, Rekha, Coleman, Courtney, Dahlén, Sven Erik, Djukanovic, Ratko, Deschildre, Antoine, Fleming, Louise, Fowler, Stephen J., Gupta, Atul, Hamelmann, Eckard, Hashimoto, Simone, Hedlin, Gunilla, Koppelman, Gerard H., Melén, Erik, Murray, Clare S., Pilette, Charles, Porsbjerg, Celeste, Pike, Katharine C., Rusconi, Franca, Williams, Clare, Ahrens, Birgit, Alter, Peter, Anckers, Freja, van den Berge, Maarten, Blumchen, Katharina, Brusselle, Guy, Clarke, Graham W., Cunoosamy, Danen, Dahlén, Barbro, Dixey, Piers, Exley, Andrew, Frey, Urs, Gaillard, Erol A., Giovannini-Chami, Lisa, Grigg, Jonathan, Hartenstein, Diana, Heaney, Liam G., Karadag, Bülent, Kaul, Susanne, Kull, Inger, Licari, Amelia, Maitland-van der Zee, Anke-Hilse, Mahler, Vera, Schoos, Ann Marie M., Nagakumar, Prasad, Negus, Jenny, Nielsen, Hanna, Pijnenburg, Mariëlle, Ramiconi, Valeria, Romagosa Vilarnau, Sofia, Principe, Stefania, Rutjes, Niels W. P., Saglani, Sejal, Seddon, Paul C, Singer, Florian, Staudinger, Heribert, Turner, Steve, Vijverberg, Susanne J, Winders, Tonya, Yasinska, Valentyna, Roberts, Graham, Sverrild, Asger, Lapperre, Therese, Khaleva, Ekaterina, Rattu, Anna, Brightling, Chris, Bush, Andrew, Bossios, Apostolos, Bourdin, Arnaud, Chung, Kian Fan, Chaudhuri, Rekha, Coleman, Courtney, Dahlén, Sven Erik, Djukanovic, Ratko, Deschildre, Antoine, Fleming, Louise, Fowler, Stephen J., Gupta, Atul, Hamelmann, Eckard, Hashimoto, Simone, Hedlin, Gunilla, Koppelman, Gerard H., Melén, Erik, Murray, Clare S., Pilette, Charles, Porsbjerg, Celeste, Pike, Katharine C., Rusconi, Franca, Williams, Clare, Ahrens, Birgit, Alter, Peter, Anckers, Freja, van den Berge, Maarten, Blumchen, Katharina, Brusselle, Guy, Clarke, Graham W., Cunoosamy, Danen, Dahlén, Barbro, Dixey, Piers, Exley, Andrew, Frey, Urs, Gaillard, Erol A., Giovannini-Chami, Lisa, Grigg, Jonathan, Hartenstein, Diana, Heaney, Liam G., Karadag, Bülent, Kaul, Susanne, Kull, Inger, Licari, Amelia, Maitland-van der Zee, Anke-Hilse, Mahler, Vera, Schoos, Ann Marie M., Nagakumar, Prasad, Negus, Jenny, Nielsen, Hanna, Pijnenburg, Mariëlle, Ramiconi, Valeria, Romagosa Vilarnau, Sofia, Principe, Stefania, Rutjes, Niels W. P., Saglani, Sejal, Seddon, Paul C, Singer, Florian, Staudinger, Heribert, Turner, Steve, Vijverberg, Susanne J, Winders, Tonya, Yasinska, Valentyna, Roberts, Graham, Sverrild, Asger, and Lapperre, Therese

Abstract

Background Effectiveness studies with biological therapies for asthma lack standardised outcome measures. The COMSA (Core Outcome Measures sets for paediatric and adult Severe Asthma) Working Group sought to develop Core Outcome Measures (COM) sets to facilitate better synthesis of data and appraisal of biologics in paediatric and adult asthma clinical studies. Methods COMSA utilised a multi-stakeholder consensus process among patients with severe asthma, adult and paediatric clinicians, pharmaceutical representatives, and health regulators from across Europe. Evidence included a systematic review of development, validity and reliability of selected outcome measures plus a narrative review and a pan-European survey to better understand patients’ and carers’ views about outcome measures. It was discussed using a modified GRADE (Grading of Recommendations Assessment, Development and Evaluation) Evidence to Decision framework. Anonymous voting was conducted using predefined consensus criteria. Results Both adult and paediatric COM sets include forced expiratory volume in 1 s (FEV1) as z-scores, annual frequency of severe exacerbations and maintenance oral corticosteroid use. Additionally, the paediatric COM set includes the Paediatric Asthma Quality of Life Questionnaire and Asthma Control Test or Childhood Asthma Control Test, while the adult COM set includes the Severe Asthma Questionnaire and Asthma Control Questionnaire-6 (symptoms and rescue medication use reported separately). Conclusions This patient-centred collaboration has produced two COM sets for paediatric and adult severe asthma. It is expected that they will inform the methodology of future clinical trials, enhance comparability of efficacy and effectiveness of biological therapies, and help assess their socioeconomic value. COMSA will inform definitions of non-response and response to biological therapy for severe asthma., Background Effectiveness studies with biological therapies for asthma lack standardised outcome measures. The COMSA (Core Outcome Measures sets for paediatric and adult Severe Asthma) Working Group sought to develop Core Outcome Measures (COM) sets to facilitate better synthesis of data and appraisal of biologics in paediatric and adult asthma clinical studies. Methods COMSA utilised a multi-stakeholder consensus process among patients with severe asthma, adult and paediatric clinicians, pharmaceutical representatives, and health regulators from across Europe. Evidence included a systematic review of development, validity and reliability of selected outcome measures plus a narrative review and a pan-European survey to better understand patients’ and carers’ views about outcome measures. It was discussed using a modified GRADE (Grading of Recommendations Assessment, Development and Evaluation) Evidence to Decision framework. Anonymous voting was conducted using predefined consensus criteria. Results Both adult and paediatric COM sets include forced expiratory volume in 1 s (FEV1) as z-scores, annual frequency of severe exacerbations and maintenance oral corticosteroid use. Additionally, the paediatric COM set includes the Paediatric Asthma Quality of Life Questionnaire and Asthma Control Test or Childhood Asthma Control Test, while the adult COM set includes the Severe Asthma Questionnaire and Asthma Control Questionnaire-6 (symptoms and rescue medication use reported separately). Conclusions This patient-centred collaboration has produced two COM sets for paediatric and adult severe asthma. It is expected that they will inform the methodology of future clinical trials, enhance comparability of efficacy and effectiveness of biological therapies, and help assess their socioeconomic value. COMSA will inform definitions of non-response and response to biological therapy for severe asthma.

Published
2023

20. Olfactory Outcomes with Dupilumab in Chronic Rhinosinusitis with Nasal Polyps

Author

Mullol, Joaquim, Bachert, Claus, Amin, Nikhil, Desrosiers, Martin, Hellings, Peter W., Han, Joseph K., Jankowski, Roger, Vodička, Jan, Gevaert, Philippe, Daizadeh, Nadia, Khan, Asif H., Kamat, Siddhesh, Patel, Naimish, Graham, Neil M.H., Ruddy, Marcella, Staudinger, Heribert, Mannent, Leda P., Mullol, Joaquim, Bachert, Claus, Amin, Nikhil, Desrosiers, Martin, Hellings, Peter W., Han, Joseph K., Jankowski, Roger, Vodička, Jan, Gevaert, Philippe, Daizadeh, Nadia, Khan, Asif H., Kamat, Siddhesh, Patel, Naimish, Graham, Neil M.H., Ruddy, Marcella, Staudinger, Heribert, and Mannent, Leda P.

Abstract

BACKGROUND: Loss of smell (LoS) is one of the most troublesome and difficult-to-treat symptoms of severe chronic rhinosinusitis with nasal polyps (CRSwNP). OBJECTIVE: To assess the impact of dupilumab on sense of smell in severe CRSwNP. METHODS: In the randomized SINUS-24 and SINUS-52 studies, adults with severe CRSwNP received dupilumab 300 mg subcutaneously or matching placebo every 2 weeks for 24 or 52 weeks, respectively. Smell was assessed using daily patient reported LoS score (0e3) and University of Pennsylvania Smell Identification Test (UPSIT; 0e40). Data from the 2 studies were pooled through week 24. Relationships between patient phenotypes and smell outcomes were also assessed. RESULTS: We randomized 724 patients (286 placebo, 438 dupilumab); mean CRSwNP duration was 11 years; 63% had prior sinonasal surgery. Mean baseline LoS was 2.74. Dupilumab produced rapid improvement in LoS, evident by day 3, which improved progressively throughout the study periods (least squares mean difference vs placebo L0.07 [95% CI L0.12 to L0.02]; nominal P < .05 at day 3, and L1.04 [L1.17 to L0.91]; P < .0001 at week 24). Dupilumab improved mean UPSIT by 10.54 (least squares mean difference vs placebo 10.57 [9.40e11.74]; P < .0001) at week 24 from baseline (score 13.90). Improvements were unaffected by CRSwNP duration, prior sinonasal surgery, or comorbid asthma and/or nonsteroidal anti-inflammatory drugeexacerbated respiratory disease. Baseline olfaction scores correlated with all measured local and systemic type 2 inflammatory markers except serum total immunoglobulin E. CONCLUSIONS: Dupilumab produced rapid and sustained improvement in sense of smell, alleviating a cardinal symptom of severe CRSwNP., Úvod: Ztráta čichu (LoS) je jednou z nejčastější problematicky a obtížně léčitelných příznaků těžké chronické rinosinusitidy s nosními polypy (CRSwNP). CÍL: Zhodnotit vliv Dupilumab na čich u těžké CRSwNP. METODY: V randomizovaných SINUS-24 a SINUS-52 studiích dostávali dospělí s těžkým CRSwNP Dupilumab 300 mg subkutánně nebo odpovídající placebo každé 2 týdny po dobu 24 nebo 52 týdnů. Čich byl hodnocen pomocí denního skóre LoS hlášeného pacientem (0e3) a testu identifikace University of Pennsylvania (UPSIT; 0e40). Údaje ze dvou studií byly shromážděny do týdne 24. Vztahy mezi pacienty byly také hodnoceny fenotypy a výsledky čichových testů. METODY: V randomizovaných SINUS-24 a SINUS-52 studiích dostávali dospělí s těžkým CRSwNP Dupilumab 300 mg subkutánně nebo odpovídající placebo každé 2 týdny po dobu 24 nebo 52 týdnů. Čich byl hodnocen pomocí denního skóre LoS hlášeného pacientem (0e3) a testu identifikace University of Pennsylvania (UPSIT; 0e40). Údaje ze 2 studií byly shromážděny do týdne 24. Byly také hodnoceny vztahy mezi fenotypy pacientů a výsledky čichových testů. VÝSLEDKY: Randomizovali jsme 724 pacientů (286 placebo, 438 Dupilumab); průměrná doba trvání CRSwNP byla 11 let; 63 % mělo předchozí sinonazální chirurgii. Průměrná výchozí hodnota LoS byla 2,74. Dupilumab způsobil rychlé zlepšení LoS, patrné do 3. dne, což se progresivně zlepšovalo v průběhu období studie (průměrný rozdíl oproti placebu L0,07 [95% CI L0,12 až L0,02]; nominální P < 0,05 v den 3 a L1,04 [L1,17 až L0,91]; P < 0,0001 v týdnu 24). Dupilumab zlepšil průměrný výsledek UPSIT o 10,54 (průměrný rozdíl oproti placebu 10,57 [9,40e11,74]; P < 0,0001) ve 24. týdnu od výchozího stavu (skóre 13,90). Zlepšení nebylo ovlivněné trváním CRSwNP, předchozí sinonazální operací, popř. komorbidním astma a/nebo nesteroidní protizánětlivé, lékově exacerbované respirační onemocnění. Základní skóre čichu korelovalo se všemi naměřenými lokálními a systémovými zánětlivými markery 2. typu, kromě celko

Published
2023

21. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA)

Author

Khaleva, Ekaterina, primary, Rattu, Anna, additional, Brightling, Chris, additional, Bush, Andrew, additional, Bossios, Apostolos, additional, Bourdin, Arnaud, additional, Chung, Kian Fan, additional, Chaudhuri, Rekha, additional, Coleman, Courtney, additional, Dahlén, Sven-Erik, additional, Djukanovic, Ratko, additional, Deschildre, Antoine, additional, Fleming, Louise, additional, Fowler, Stephen J., additional, Gupta, Atul, additional, Hamelmann, Eckard, additional, Hashimoto, Simone, additional, Hedlin, Gunilla, additional, Koppelman, Gerard H., additional, Melén, Erik, additional, Murray, Clare S., additional, Pilette, Charles, additional, Porsbjerg, Celeste, additional, Pike, Katharine C., additional, Rusconi, Franca, additional, Williams, Clare, additional, Ahrens, Birgit, additional, Alter, Peter, additional, Anckers, Freja, additional, van den Berge, Maarten, additional, Blumchen, Katharina, additional, Brusselle, Guy, additional, Clarke, Graham W., additional, Cunoosamy, Danen, additional, Dahlén, Barbro, additional, Dixey, Piers, additional, Exley, Andrew, additional, Frey, Urs, additional, Gaillard, Erol A., additional, Giovannini-Chami, Lisa, additional, Grigg, Jonathan, additional, Hartenstein, Diana, additional, Heaney, Liam G., additional, Karadag, Bülent, additional, Kaul, Susanne, additional, Kull, Inger, additional, Licari, Amelia, additional, Maitland-van der Zee, Anke H., additional, Mahler, Vera, additional, Schoos, Ann-Marie M., additional, Nagakumar, Prasad, additional, Negus, Jenny, additional, Nielsen, Hanna, additional, Paton, James, additional, Pijnenburg, Mariëlle, additional, Ramiconi, Valeria, additional, Romagosa Vilarnau, Sofia, additional, Principe, Stefania, additional, Rutjes, Niels, additional, Saglani, Sejal, additional, Seddon, Paul, additional, Singer, Florian, additional, Staudinger, Heribert, additional, Turner, Steve, additional, Vijverberg, Susanne, additional, Winders, Tonya, additional, Yasinska, Valentyna, additional, and Roberts, Graham, additional

Published
2022
Full Text
View/download PDF

24. 3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

Author

Porsbjerg, Celeste, primary, Maitland-van der Zee, Anke H., additional, Brusselle, Guy, additional, Canonica, Giorgio Walter, additional, Agusti, Alvar, additional, Faner, Rosa, additional, Vogelmeier, Claus F., additional, Nawijn, Martijn, additional, van den Berge, Maarten, additional, Rusconi, Franca, additional, Pilette, Charles, additional, Ramiconi, Valeria, additional, Coleman, Courtney, additional, Chaudhuri, Rekha, additional, Chung, Kian Fan, additional, Wedzicha, Jadwiga, additional, Saglani, Sejla, additional, Van der Schee, Marc P., additional, Heaney, Liam, additional, Bourdin, Arnaud, additional, Roberts, Graham, additional, Djukanovic, Ratko, additional, Kuna, Piotr, additional, Kupczyk, Maciej, additional, Axmann, Judith, additional, Staudinger, Heribert, additional, Clarke, Graham W., additional, Dahlen, Sven Erik, additional, and Brightling, Chris, additional

Published
2021
Full Text
View/download PDF

25. Late Breaking Abstract - Immunomodulatory and clinical effects of RIPK1 inhibitor SAR443122 in patients with severe COVID-19

Author

Clot, Pierre-Francois, primary, Farenc, Christine, additional, Suratt, Benjamin, additional, Krahnke, Tillmann, additional, Tardat, Agnes, additional, Florian, Peter, additional, Pomponio, Robert, additional, Patel, Naimish, additional, Wiekowski, Maria, additional, Lin, Yong, additional, Terrier, Benjamin, additional, and Staudinger, Heribert, additional

Published
2021
Full Text
View/download PDF

27. 3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD.

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Centre de l'allergie, UCL - (SLuc) Service de pneumologie, Porsbjerg, Celeste, Maitland-van der Zee, Anke H, Brusselle, Guy, Canonica, Giorgio Walter, Agusti, Alvar, Faner, Rosa, Vogelmeier, Claus F, Nawijn, Martijn, van den Berge, Maarten, Rusconi, Franca, Pilette, Charles, Ramiconi, Valeria, Coleman, Courtney, Chaudhuri, Rekha, Chung, Kian Fan, Wedzicha, Jadwiga, Saglani, Sejla, Van der Schee, Marc P, Heaney, Liam, Bourdin, Arnaud, Roberts, Graham, Djukanovic, Ratko, Kuna, Piotr, Kupczyk, Maceij, Axmann, Judith, Staudinger, Heribert, Clarke, Graham W, Dahlen, Sven Erik, Brightling, Chris, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Centre de l'allergie, UCL - (SLuc) Service de pneumologie, Porsbjerg, Celeste, Maitland-van der Zee, Anke H, Brusselle, Guy, Canonica, Giorgio Walter, Agusti, Alvar, Faner, Rosa, Vogelmeier, Claus F, Nawijn, Martijn, van den Berge, Maarten, Rusconi, Franca, Pilette, Charles, Ramiconi, Valeria, Coleman, Courtney, Chaudhuri, Rekha, Chung, Kian Fan, Wedzicha, Jadwiga, Saglani, Sejla, Van der Schee, Marc P, Heaney, Liam, Bourdin, Arnaud, Roberts, Graham, Djukanovic, Ratko, Kuna, Piotr, Kupczyk, Maceij, Axmann, Judith, Staudinger, Heribert, Clarke, Graham W, Dahlen, Sven Erik, and Brightling, Chris

Abstract

The 3TR (Taxonomy, Treatments, Targets and Remission) consortium is the largest IMI (Innovative Medicine Initiative) project ever started in the field of immune diseases (https://3tr-imi.eu/). 3TR is unique in bringing several medical specialties, encompassing respiratory medicine, rheumatology, neurology and gastroenterology, together, to study disease mechanisms across seven disease entities: asthma, COPD, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, ulcerative colitis and Crohn's disease. [...]

Published
2021

28. 3TR:A pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

Author

Porsbjerg, Celeste, Maitland-Van der Zee, Anke H., Brusselle, Guy, Canonica, Giorgio Walter, Agusti, Alvar, Faner, Rosa, Vogelmeier, Claus F., Nawijn, Martijn, van den Berge, Maarten, Rusconi, Franca, Pilette, Charles, Ramiconi, Valeria, Coleman, Courtney, Chaudhuri, Rekha, Chung, Kian Fan, Wedzicha, Jadwiga, Saglani, Sejla, van der Schee, Marc P., Heaney, Liam, Bourdin, Arnaud, Roberts, Graham, Djukanovic, Ratko, Kuna, Piotr, Kupczyk, Maciej, Axmann, Judith, Staudinger, Heribert, Clarke, Graham W., Dahlen, Sven Erik, Brightling, Chris, Porsbjerg, Celeste, Maitland-Van der Zee, Anke H., Brusselle, Guy, Canonica, Giorgio Walter, Agusti, Alvar, Faner, Rosa, Vogelmeier, Claus F., Nawijn, Martijn, van den Berge, Maarten, Rusconi, Franca, Pilette, Charles, Ramiconi, Valeria, Coleman, Courtney, Chaudhuri, Rekha, Chung, Kian Fan, Wedzicha, Jadwiga, Saglani, Sejla, van der Schee, Marc P., Heaney, Liam, Bourdin, Arnaud, Roberts, Graham, Djukanovic, Ratko, Kuna, Piotr, Kupczyk, Maciej, Axmann, Judith, Staudinger, Heribert, Clarke, Graham W., Dahlen, Sven Erik, and Brightling, Chris

Published
2021

30. Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function

Author

Pavord,Ian D, Siddiqui,Salman, Papi,Alberto, Corren,Jonathan, Sher,Lawrence D, Bardin,Philip, Langton,David, Park,Hae-Sim, Rice,Megan S, Deniz,Yamo, Rowe,Paul, Staudinger,Heribert W, Patel,Naimish, Ruddy,Marcella, Graham,Neil MH, and Teper,Ariel

Subjects
FEV1, exacerbation, FEV1, asthma, biomarkers, dupilumab, exacerbation, dupilumab, Journal of Asthma and Allergy, Socio-culturale, biomarkers, asthma, respiratory tract diseases, Original Research
Abstract

Ian D Pavord,1 Salman Siddiqui,2 Alberto Papi,3 Jonathan Corren,4 Lawrence D Sher,5 Philip Bardin,6 David Langton,7 Hae-Sim Park,8 Megan S Rice,9 Yamo Deniz,10 Paul Rowe,11 Heribert W Staudinger,11 Naimish Patel,11 Marcella Ruddy,10 Neil MH Graham,10 Ariel Teper11 1Respiratory Medicine Unit and Oxford Respiratory National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK; 2University of Leicester and Leicester National Institute for Health Research Biomedical Research Centre (Respiratory Theme), Leicester, UK; 3Department of Respiratory Medicine, University of Ferrara, Ferrara, Italy; 4David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 5Peninsula Research Associates, Rolling Hills Estate, CA, USA; 6Department of Lung and Sleep Medicine, Monash University and Medical Centre, Clayton, Melbourne, VIC, Australia; 7Department of Thoracic Medicine, Frankston Hospital, Frankston, Melbourne, VIC, Australia; 8Ajou University Hospital, Suwon, South Korea; 9Sanofi, Cambridge, MA, USA; 10Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 11Sanofi, Bridgewater, NJ, USACorrespondence: Ian D PavordNDM Research Building, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7FZ, UKTel +44 (0)1865 612897Email ian.pavord@ndm.ox.ac.ukPurpose: The Phase 3 LIBERTY ASTHMA QUEST study in patients aged ≥ 12 years with uncontrolled, moderate-to-severe asthma demonstrated the efficacy and safety of dupilumab 200 mg and 300 mg every 2 weeks (q2w) vs matched placebo in the overall population. This post hoc analysis assessed dupilumab efficacy by disease severity as evidenced by baseline % predicted forced expiratory volume in 1 second (FEV1) and dose of inhaled corticosteroids (ICS).Patients and Methods: Severe asthma exacerbation rates, change from baseline in FEV1, asthma control, quality of life, and fractional exhaled nitric oxide (FeNO) levels over the 52-week treatment period were assessed in patients with elevated type 2 inflammation biomarkers stratified by ICS dose and FEV1% predicted at baseline.Results: In patients with elevated baseline eosinophils, dupilumab 200 mg and 300 mg q2w vs placebo reduced severe exacerbation rates by 50% (P=0.06) and 67% (P=0.001), respectively, in those with medium-dose ICS/FEV1% predicted 60– 90%, and by 59% (P< 0.001) and 47% (P=0.006) in those with high-dose ICS/FEV1% predicted < 60%, improved pre-bronchodilator FEV1 at Week 12 by 0.16L (P=0.005) and 0.08L (P=0.13), and by 0.20L (P=0.003) and 0.21L (P< 0.001), respectively, in the same subgroups. Dupilumab vs placebo also improved asthma control and quality of life and suppressed FeNO levels in all patient subgroups with similar results observed irrespective of baseline biomarker status or disease severity.Conclusion: Dupilumab reduced severe exacerbations and improved lung function, asthma control and quality of life in patients with elevated baseline eosinophils irrespective of baseline ICS dose or FEV1% predicted.Keywords: asthma, biomarkers, dupilumab, exacerbation, FEV1

Published
2020

34. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

Author

Deleuran, Mette, primary, Thaçi, Diamant, additional, Beck, Lisa A., additional, de Bruin-Weller, Marjolein, additional, Blauvelt, Andrew, additional, Forman, Seth, additional, Bissonnette, Robert, additional, Reich, Kristian, additional, Soong, Weily, additional, Hussain, Iftikhar, additional, Foley, Peter, additional, Hide, Michihiro, additional, Bouaziz, Jean-David, additional, Gelfand, Joel M., additional, Sher, Lawrence, additional, Schuttelaar, Marie L.A., additional, Wang, Chen, additional, Chen, Zhen, additional, Akinlade, Bolanle, additional, Gadkari, Abhijit, additional, Eckert, Laurent, additional, Davis, John D., additional, Rajadhyaksha, Manoj, additional, Staudinger, Heribert, additional, Graham, Neil M.H., additional, Pirozzi, Gianluca, additional, and Ardeleanu, Marius, additional

Published
2020
Full Text
View/download PDF

35. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis

Author

Worm, Margitta, primary, Simpson, Eric L., additional, Thaçi, Diamant, additional, Bissonnette, Robert, additional, Lacour, Jean-Philippe, additional, Beissert, Stefan, additional, Kawashima, Makoto, additional, Ferrándiz, Carlos, additional, Smith, Catherine H., additional, Beck, Lisa A., additional, Chan, Kuo-Chen, additional, Chen, Zhen, additional, Akinlade, Bolanle, additional, Hultsch, Thomas, additional, Staudinger, Heribert, additional, Gadkari, Abhijit, additional, Eckert, Laurent, additional, Davis, John D., additional, Rajadhyaksha, Manoj, additional, Graham, Neil M. H., additional, Pirozzi, Gianluca, additional, Stahl, Neil, additional, Yancopoulos, George D., additional, and Ardeleanu, Marius, additional

Published
2020
Full Text
View/download PDF

36. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

Author

Simpson, Eric L., primary, Paller, Amy S., additional, Siegfried, Elaine C., additional, Boguniewicz, Mark, additional, Sher, Lawrence, additional, Gooderham, Melinda J., additional, Beck, Lisa A., additional, Guttman-Yassky, Emma, additional, Pariser, David, additional, Blauvelt, Andrew, additional, Weisman, Jamie, additional, Lockshin, Benjamin, additional, Hultsch, Thomas, additional, Zhang, Qin, additional, Kamal, Mohamed A., additional, Davis, John D., additional, Akinlade, Bolanle, additional, Staudinger, Heribert, additional, Hamilton, Jennifer D., additional, Graham, Neil M. H., additional, Pirozzi, Gianluca, additional, Gadkari, Abhijit, additional, Eckert, Laurent, additional, Stahl, Neil, additional, Yancopoulos, George D., additional, Ruddy, Marcella, additional, and Bansal, Ashish, additional

Published
2020
Full Text
View/download PDF

37. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Author

Bachert, Claus, primary, Han, Joseph K, additional, Desrosiers, Martin, additional, Hellings, Peter W, additional, Amin, Nikhil, additional, Lee, Stella E, additional, Mullol, Joaquim, additional, Greos, Leon S, additional, Bosso, John V, additional, Laidlaw, Tanya M, additional, Cervin, Anders U, additional, Maspero, Jorge F, additional, Hopkins, Claire, additional, Olze, Heidi, additional, Canonica, G Walter, additional, Paggiaro, Pierluigi, additional, Cho, Seong H, additional, Fokkens, Wytske J, additional, Fujieda, Shigeharu, additional, Zhang, Mei, additional, Lu, Xin, additional, Fan, Chunpeng, additional, Draikiwicz, Steven, additional, Kamat, Siddhesh A, additional, Khan, Asif, additional, Pirozzi, Gianluca, additional, Patel, Naimish, additional, Graham, Neil M H, additional, Ruddy, Marcella, additional, Staudinger, Heribert, additional, Weinreich, David, additional, Stahl, Neil, additional, Yancopoulos, George D, additional, and Mannent, Leda P, additional

Published
2019
Full Text
View/download PDF

42. Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis

Author

Bachert, Claus, primary, Hellings, Peter W., additional, Mullol, Joaquim, additional, Hamilos, Daniel L., additional, Gevaert, Philippe, additional, Naclerio, Robert M., additional, Joish, Vijay N., additional, Chao, Jingdong, additional, Mannent, Leda P., additional, Amin, Nikhil, additional, Abbe, Adeline, additional, Taniou, Christine, additional, Fan, Chunpeng, additional, Pirozzi, Gianluca, additional, Graham, Neil M. H., additional, Mahajan, Puneet, additional, Staudinger, Heribert, additional, and Khan, Asif, additional

Published
2019
Full Text
View/download PDF

43. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP

Author

Bachert, Claus, primary, Zinreich, S. James, additional, Hellings, Peter W., additional, Mullol, Joaquim, additional, Hamilos, Daniel L., additional, Gevaert, Philippe, additional, Naclerio, Robert M., additional, Amin, Nikhil, additional, Joish, Vikay N., additional, Fan, Chunpeng, additional, Zhang, Donghui, additional, Staudinger, Heribert, additional, Pirozzi, Gianluca, additional, Graham, Neil M.H., additional, Khan, Asif, additional, and Mannent, Leda P., additional

Published
2019
Full Text
View/download PDF

44. Dupilimab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Asthma by Body Mass Index

Author

Korn, Stephanie, primary, Busse, William W., additional, Echave-Sustaeta, José María, additional, Dixon, Anne E., additional, Mucsi, Janos, additional, Rice, Megan S., additional, Deniz, Yamo, additional, Rowe, Paul, additional, Staudinger, Heribert W., additional, Amin, Nikhil, additional, Ruddy, Marcella, additional, Graham, Neil M.H., additional, and Teper, Ariel, additional

Published
2019
Full Text
View/download PDF

45. Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials

Author

Mullol, Joaquim, primary, Laidlaw, Tanya M., additional, Amin, Nikhil, additional, Bachert, Claus, additional, Han, Joseph K., additional, Hellings, Peter W., additional, Canonica, G. Walter, additional, Cho, Seong H., additional, Maspero, Jorge F., additional, Desrosiers, Martin, additional, Hopkins, Claire, additional, Paggiaro, Pierluigi, additional, Zhang, Mei, additional, Lu, Xin, additional, Patel, Naimish, additional, Graham, Neil M.H., additional, Staudinger, Heribert, additional, and Mannent, Leda P., additional

Published
2019
Full Text
View/download PDF

46. Dupilumab (DPL) Improves Upper and Lower Airway Outcomes in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) with Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): Pooled Results From SINUS-24, SINUS-52 Phase 3 Trials

Author

Laidlaw, Tanya M., primary, Mullol, Joaquim, additional, Canonica, G. Walter, additional, Bachert, Claus, additional, Han, Joseph K., additional, Zhang, Mei, additional, Lu, Xin, additional, Patel, Naimish, additional, Graham, Neil Mh, additional, Staudinger, Heribert, additional, Mannent, Leda P., additional, and Amin, Nikhil, additional

Published
2019
Full Text
View/download PDF

47. Dupilumab Efficacy in Asthma Patients With FEV1 60–80% Predicted on Medium-Dose ICS: liberty asthma quest Study

Author

Papi, Alberto, primary, Pavord, Ian D., additional, Fitzgerald, J. Mark, additional, Corren, Jonathan, additional, Bardin, Philip, additional, Park, Hae Sim, additional, Rice, Megan S., additional, Deniz, Yamo, additional, Rowe, Paul, additional, Staudinger, Heribert, additional, Amin, Nikhil, additional, Ruddy, Marcella, additional, Graham, Neil M.H., additional, and Teper, Ariel, additional

Published
2019
Full Text
View/download PDF

48. Dupilumab Improves Lung Function and Reduces Severe Exacerbation Rate in Patients With Uncontrolled, Moderate-to-Severe Asthma With or Without Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study

Author

Busse, William W., primary, Maspero, Jorge F., additional, Hanania, Nicola A., additional, FitzGerald, J. Mark, additional, Ford, Linda B., additional, Rice, Megan, additional, Lu, Yufang, additional, Rowe, Paul, additional, Staudinger, Heribert, additional, Amin, Nikhil, additional, Ruddy, Marcella, additional, Graham, Neil M.H., additional, and Teper, Ariel, additional

Published
2019
Full Text
View/download PDF

49. Dupilumab Consistently Improves Rhinoconjunctivitis-Specific Health-Related Quality of Life in Patients With Uncontrolled, Moderate-to-Severe Asthma and Comorbid Allergic Rhinitis: Results from the Phase 3 LIBERTY ASTHMA QUEST Study

Author

Bousquet, Jean, primary, Maspero, Jorge F., additional, Chipps, Bradley E., additional, Corren, Jonathan, additional, FitzGerald, J. Mark, additional, Chen, Zhen, additional, Lu, Yufang, additional, Rowe, Paul, additional, Staudinger, Heribert, additional, Ruddy, Marcella, additional, Graham, Neil M.H., additional, Kamat, Siddhesh, additional, Amin, Nikhil, additional, Teper, Ariel, additional, and Khan, Asif, additional

Published
2019
Full Text
View/download PDF

50. Dupilumab Suppresses Inflammatory Biomarkers in Asthma Patients With or Without Allergic Rhinitis: Post Hoc Analysis of the LIBERTY ASTHMA QUEST Study

Author

Corren, Jonathan, primary, Bousquet, Jean, additional, Busse, William W., additional, Maspero, Jorge F., additional, Hanania, Nicola A., additional, Ford, Linda B., additional, Rice, Megan, additional, Lu, Yufang, additional, Rowe, Paul, additional, Harel, Sivan, additional, Staudinger, Heribert, additional, Ruddy, Marcella, additional, Graham, Neil M.H., additional, Amin, Nikhil, additional, and Teper, Ariel, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results